We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
But8.5
Butyrate Research
Likely helpsHigh safety
47 peer-reviewed studies
What the evidence says
Likely helps
Butyrate appears to help in 5 of 5 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 2018–2026 with a typical study size of 66 participants.
Based on 47 studies · 7 meta-analyses · 15 RCTs · 37,452 total participants
Confidence
High
What the studies found
5helped· 42 more without graded effect data
By outcome
Digestive healthImproved gut lining integrity and reduced GI discomfort within 2-4 weeks · 2-4 weeks
Likely helps43 studies
Therapeutic & clinical
Mostly mechanism / observational8 studies
InflammationImproved gut barrier and reduced inflammation · 2-4 weeks
Mostly mechanism / observational4 studies
Glucose & metabolicSCFA supporting insulin sensitivity and mitochondrial function · 4-8 weeks
Mostly mechanism / observational4 studies
Heart & blood pressure
Mostly mechanism / observational3 studies
Depression & mood
Mostly mechanism / observational3 studies
Cognitive function
Too few graded studies2 studies
Anxiety & stress
Too few graded studies2 studies
Immune supportStrengthens gut barrier integrity and modulates immune response · 4-8 weeks
Too few graded studies2 studies
Weight management
Too few graded studies1 study
Cholesterol & lipids
Too few graded studies1 study
Bone health
Too few graded studies1 study
Skin health
Too few graded studies1 study
Safety profile
Too few graded studies1 study
By the numbers
Pulled from 27 studies with measurable effects
Likely real effects
75%
across studies
People studied
37k
typical study: 66 people
Strongest designs
22
7 pooled, 15 randomised
Showed benefit
100%
5/5 studies
How long studies ran
1–4 weeks
1
Populations Studied
Patients with depressive disorder1
Patients with depression, bipolar disorder, schizophrenia, and anxiety1
Patients with major depressive disorder, bipolar disorder and schizophrenia1
IBD patients1
Active research area
38 studies in the last 5 years · Latest meta-analysis: 2026
20182026
1Chao1 diversity indexMeta-AnalysisCited 86×n=2,091 · very large study2023
This meta-analysis examined the effects of Butyrate.
Gao M et al. · Translational psychiatry (2023)
Noticeable benefit
← WorseNo effectBetter →
A random-effects model with restricted maximum-likelihood estimator was used to synthesize the effect size (assessed by standardized mean difference [SMD]) across studies.
In subgroup analyses with regional variations(east/west) as a predictor, patients who were in the West had a lower Chao1 level (SMD -0.42[-0.74 to -0.10]).
Subgroup meta-analysis showed Firmicutes level was decreased in patients with depressive disorder who were medication-free (SMD -1.54[-2.36 to -0.72]), but Bacteroidetes level was increased (SMD -0.90[0.07 to 1.72]).
2Phylogenetic diversity in psychiatric disordersMeta-AnalysisCited 534×n=1,519 · large study2021
This systematic review and meta-analysis found that gut microbiota perturbations were associated with a transdiagnostic pattern with a depletion of certain anti-inflammatory butyrate-producing bacteria and an enrichment of pro-inflammatory bacteria in patients with depression, bipolar disorder, schizophrenia, and anxiety.
Nikolova VL et al. · JAMA psychiatry (2021)
Noticeable benefit
← WorseNo effectBetter →
There was a small decrease in phylogenetic diversity (SMD = -0.24; 95% CI, -0.47 to -0.001) and no significant differences in Shannon and Simpson indices.
4Gut microbiota composition in psychiatric disordersSystematic ReviewCited 374×n=2,510 · very large study2022
This systematic-review examined the effects of Butyrate.
McGuinness AJ et al. · Molecular psychiatry (2022)
We also observed substantial heterogeneity across studies with regards to methodologies and reporting.
Further prospective and experimental research using new tools and robust guidelines hold promise for improving our understanding of the role of the gut microbiota in mental and brain health and the development of interventions based on modification of gut microbiota.
5Meta-AnalysisCited 482×n=2,099 · very large study2018
Dietary fiber intervention, particularly involving fructans and galacto-oligosaccharides, leads to higher fecal abundance of Bifidobacterium and Lactobacillus spp. but does not affect α-diversity.
So D et al. · The American journal of clinical nutrition (2018)
Dietary fiber intervention, particularly involving fructans and galacto-oligosaccharides, leads to higher fecal abundance of Bifidobacterium and Lactobacillus spp. but does not affect α-diversity.
Further research is required to better understand the role of individual fiber types on the growth of microbes and the overall gut microbial community.
This review was registered at PROSPERO as CRD42016053101.
6Biologics response prediction in IBDSystematic ReviewCited 36×n=38 · small study2024
IBD patients who responded well to vedolizumab treatment had higher levels of specific bacteria that produce butyrate, along with increased levels of metabolites such as butyrate, branched-chain am...
Wang C et al. · Microbiological research (2024)
IBD patients who responded well to vedolizumab treatment had higher levels of specific bacteria that produce butyrate, along with increased levels of metabolites such as butyrate, branched-chain amino acids and acetamide following vedolizumab treatment.
Crohn's disease patients who responded positively to ustekinumab treatment showed higher levels of Faecalibacterium and lower levels of Escherichia/Shigella.
Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Sasaki M et al. · Allergy (2024)
Overall, there was some evidence showing that the three main SCFAs (acetate, propionate and butyrate) in the first few years of life had a protective effect against allergic diseases, especially for atopic dermatitis, wheeze or asthma and IgE-mediated food allergy in childhood.
The association between each SCFA and allergic disease appeared to be different by disease and the age of assessment.
Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Our research found universally applicable biomarkers and investigated their potential roles in promoting human health at high altitudes.
Zhao H et al. · Gut microbes (2024)
Functional analysis and qPCR revealed that butyrate may be a functional metabolite in high-altitude adaptation.
A high-altitude rat model showed that butyrate reduced intestinal damage caused by high altitudes.
According to cell experiments, butyrate may downregulate hypoxia-inducible factor-1α (HIF-1α) expression and blunt cellular responses to hypoxic stress.
In this study, we demonstrated that the promising substate (prebiotics), microbe (probiotics), metabolite (postbiotics), and target are suitable for obsesity treatment, providing a microbiome basis for further research.
Oh KK et al. · Cells (2022)
Then, we implemented protein-protein interaction (PPI) networks with 342 overlapping target, another subnetwork was constructed with the top 30% degree centrality (DC), and the final core networks were obtained after screening the top 30% betweenness centrality (BC).
The final core targets were IL6, AKT1, and ALB.
We showed that the three core targets interacted with three other components via the MSMT network in alleviating obesity, i.e., four microbiota, two substrates, and six metabolites.
Although a definitive interpretation is limited by the cross-sectional design of published reports, we integrated findings of microbial composition and downstream functional pathways and metabolites, offering possible explanations regarding age-related processes.
Badal VD et al. · Nutrients (2020)
Beta diversity distances significantly differed across various developmental stages and were different even between oldest-old and younger-old adults.
Differences in taxonomic composition and functional potential varied across studies, but Akkermansia was most consistently reported to be relatively more abundant with aging, whereas Faecalibacterium, Bacteroidaceae, and Lachnospiraceae were relatively reduced.
Although a definitive interpretation is limited by the cross-sectional design of published reports, we integrated findings of microbial composition and downstream functional pathways and metabolites, offering possible explanations regarding age-related processes.
11Gut-brain health and systemic inflammationSystematic Review2026
Therapeutic strategies that restore BPB populations and butyrate levels, such as prebiotics, dietary fiber, and microbiota-targeted interventions, hold promise for mitigating inflammation and enhancing systemic health through microbiome modulation.
Snodgrass JL et al. · International journal of molecular sciences (2026)
Butyrate supports colonocyte energy metabolism, reinforces epithelial barrier function, regulates goblet cell mucus production, and exerts anti-inflammatory effects via histone deacetylase inhibition and G-protein-coupled receptor signaling.
The depletion of BPB and the resultant butyrate deficiency may represent a unifying pathophysiological mechanism underlying these conditions.
Therapeutic strategies that restore BPB populations and butyrate levels, such as prebiotics, dietary fiber, and microbiota-targeted interventions, hold promise for mitigating inflammation and enhancing systemic health through microbiome modulation.
12gut microbiota and short-chain fatty acids in cardiometabolic HFpEFSystematic Review2026
Targeting gut-heart axis and SCFAs pathways may represent a biologically plausible and low-risk approach that could help attenuate inflammation and metabolic dysfunctions in patients with cardiometabolic HFpEF, offering novel potential therapeutic targets for their management.
This review summarizes current evidence linking gut microbiota dysfunction to cardiometabolic HFpEF, elucidates the mechanistic role of SCFAs, and discusses nutritional approaches aimed at enhancing their production and activity.
Targeting gut-heart axis and SCFAs pathways may represent a biologically plausible and low-risk approach that could help attenuate inflammation and metabolic dysfunctions in patients with cardiometabolic HFpEF, offering novel potential therapeutic targets for their management.
14Immunity, infections, inflammation and vaccine responsesSystematic Review2025
Further research is needed to clarify the mechanisms involved and to optimize health applications.
Arioz Tunc H et al. · Critical reviews in food science and nutrition (2025)
A systematic review of human studies showed that prebiotics, including GOS, FOS, and 2'-fucosyllactose (2FL), reduced infections and increased IgA in healthy infants, while yeast β-glucan reduced respiratory infection symptoms in healthy adults.
Yeast β-glucan and GOS supplementation resulted in improvements in NK cell activity.
Some effects on vaccine efficacy were noted in young adults, but the overall impact of NDCs and prebiotics on vaccination and systemic inflammation was inconsistent.
15Butyrate effectiveness in Parkinson's diseaseSystematic Review2025
Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences.
Abreu AE et al. · Neuroscience bulletin (2025)
This review examines butyrate's origins, functions, and mechanisms in the gut, its impact on the gut-brain axis, and its relevance in both "brain-first" and "gut-first" PD models.
We also explore the effects of butyrate supplementation in animal models and human clinical studies, highlighting its promise as a therapeutic agent for PD.
The understanding of butyrate as a versatile metabolite may pave the way for innovative strategies to prevent or manage PD, stressing the need for integrated approaches targeting both the nervous and gastrointestinal systems.
Butyrate may be an effective adjunct treatment for active UC patients by reducing biomarkers of inflammation, upregulation of circadian-clock genes and improving sleep quality and QoL.
Firoozi D et al. · Lipids in health and disease (2024)
Butyrate may be an effective adjunct treatment for active UC patients by reducing biomarkers of inflammation, upregulation of circadian-clock genes and improving sleep quality and QoL.